Generally, these syndromes are distinguished into three different categories (1): myeloid neoplasms without a preexisting disorder or organ dysfunction (e.g. CEBPA, DDX41), (2) myeloid neoplasms with a preexisting platelet disorder (ANKRD26, ETV6, RUNX1) and (3) myeloid neoplasms with potential other organ dysfunctions. This evidence concerns the gene RUNX1 and myeloid neoplasm.